Adaptimmune And Astellas Team Up For Off-The-Shelf T-Cell Therapies

Could Be Worth $900m

 
• By Kevin Grogan
Suit_Battery
Data boost and Astellas Deal Revitalize Adaptimmune • Source: Shutterstock

More from Immuno-oncology

More from Anticancer